tenecteplase + tirofiban

Tenecteplase + tirofiban is a combination therapy used primarily in the management of acute myocardial infarction (heart attack). Tenecteplase is a genetically engineered variant of tissue plasminogen activator (tPA) that acts as a thrombolytic agent, promoting the conversion of plasminogen to plasmin and thereby dissolving fibrin-rich blood clots. Tirofiban is an antiplatelet agent that functions as a glycoprotein IIb/IIIa receptor antagonist, inhibiting platelet aggregation and preventing further clot formation. The combination has been studied for its potential to enhance reperfusion and ST-segment resolution in patients with ST-segment elevation myocardial infarction (STEMI), with evidence suggesting more rapid and complete microcirculatory perfusion compared to tenecteplase alone[8][3][1].

Other names

TNK-tPA (for tenecteplase)